-
1
-
-
73349115219
-
Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up
-
Barbaglia G, Macia F, Comas M, et al. Trends in hormone therapy use before and after publication of the Women's Health Initiative trial: 10 years of follow-up. Menopause 2009;16:1061-4
-
(2009)
Menopause
, vol.16
, pp. 1061-4
-
-
Barbaglia, G.1
Macia, F.2
Comas, M.3
-
2
-
-
0042018741
-
Breast cancer and hormone-replacement therapy in the Million Women Study
-
DOI 10.1016/S0140-6736(03)14065-2
-
Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27 (Pubitemid 36999703)
-
(2003)
Lancet
, vol.362
, Issue.9382
, pp. 419-427
-
-
Beral, V.1
-
3
-
-
84855248789
-
-
Estrogen and progestogen use in postmenopausal women
-
Estrogen and progestogen use in postmenopausal women: 2010
-
-
-
-
4
-
-
77949345161
-
-
Position statement of The North American Menopause Society
-
position statement of The North American Menopause Society. Menopause 2010;17:242-5
-
(2010)
Menopause
, vol.17
, pp. 242-5
-
-
-
7
-
-
67650021834
-
Benefi ts and risks of postmenopausal hormone therapy when it is initiated soon after menopause
-
Prentice RL, Manson JE, Langer RD, et al. Benefi ts and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009;170:12-23
-
(2009)
Am J Epidemiol
, vol.170
, pp. 12-23
-
-
Prentice, R.L.1
Manson, J.E.2
Langer, R.D.3
-
8
-
-
84855248787
-
-
Pristiq [package insert] Philadelphia PA Wyeth Pharmaceuticals Inc
-
Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc., 2009
-
-
-
-
9
-
-
37549033111
-
Study 315 investigators. Effi cacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial
-
Speroff L, Gass M, Constantine G, Olivier S, Study 315 investigators. Effi cacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial. Obstet Gynecol 2008 111 77-87
-
(2008)
Obstet Gynecol
, vol.111
, pp. 77-87
-
-
Speroff, L.1
Gass, M.2
Constantine, G.3
Olivier, S.4
-
10
-
-
58749098561
-
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine effi cacy and safety for the treatment of vasomotor symptoms associated with menopause
-
e1-172.e10
-
Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine effi cacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-172.e10
-
(2009)
Am J Obstet Gynecol
, vol.200
, pp. 172
-
-
Archer, D.F.1
Seidman, L.2
Constantine, G.D.3
Pickar, J.H.4
Olivier, S.5
-
11
-
-
60849107728
-
Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A doubleblind, randomized, placebo-controlled trial of effi cacy and safety
-
e1-238.e10
-
Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S, Study 319 investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A doubleblind, randomized, placebo-controlled trial of effi cacy and safety. Am J Obstet Gynecol 2009;200:238.e1-238.e10
-
(2009)
Am J Obstet Gynecol
, vol.200
, pp. 238
-
-
Archer, D.F.1
Dupont, C.M.2
Constantine, G.D.3
Pickar, J.H.4
Olivier, S.5
-
12
-
-
13944279222
-
Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day
-
DOI 10.1016/j.maturitas.2004.06.001
-
Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot fl ushes and sweats per day. Maturitas 2005;50:222-30 (Pubitemid 40269905)
-
(2005)
Maturitas
, vol.50
, Issue.3
, pp. 222-230
-
-
Landgren, M.B.1
Helmond, F.A.2
Engelen, S.3
-
13
-
-
0036146189
-
Tibolone for postmenopausal women: Systematic review of randomized trials
-
DOI 10.1210/jc.87.1.16
-
Modelska K, Cummings S. Tibolone for postmenopausal women: Systematic review of randomized trials. J Clin Endocrinol Metab 2002;87:16-23 (Pubitemid 34084663)
-
(2002)
Journal of Clinical Endocrinology and Metabolism
, vol.87
, Issue.1
, pp. 16-23
-
-
Modelska, K.1
Cummings, S.2
-
14
-
-
58749098915
-
Safety and effi cacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial
-
Kenemans P, Bundred NJ, Foidart JM, et al. Safety and effi cacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-46
-
(2009)
Lancet Oncol
, vol.10
, pp. 135-46
-
-
Kenemans, P.1
Bundred, N.J.2
Foidart, J.M.3
-
15
-
-
84855217832
-
-
European Medicines Agency Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Defi ciency Symptoms in Postmenopausal Women European Medicines Agency, 1-11. 10-13-2005
-
European Medicines Agency. Guideline on Clinical Investigation of Medicinal Products for Hormone Replacement Therapy of Oestrogen Defi ciency Symptoms in Postmenopausal Women. European Medicines Agency, 1-11. 10-13-2005
-
-
-
-
16
-
-
84855237363
-
-
Food and Drug Administration U.S. Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry-Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation
-
Food and Drug Administration, U.S. Department of Health and Human Services, Center for Drug Evaluation and Research. Guidance for Industry-Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Recommendations for Clinical Evaluation, 2003
-
-
-
-
18
-
-
0032550785
-
Constructing a standard climacteric scale
-
DOI 10.1016/S0378-5122(98)00025-5, PII S0378512298000255
-
Greene JG. Constructing a standard climacteric scale. Maturitas 1998;29:25-31 (Pubitemid 28247565)
-
(1998)
Maturitas
, vol.29
, Issue.1
, pp. 25-31
-
-
Greene, J.G.1
-
19
-
-
0036227699
-
A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: Effects on symptom control, bleeding pattern, lipid profile and tolerability
-
Baracat EC, Barbosa IC, Giordano MG , et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: Effects on symptom control, bleeding pattern, lipid profi le and tolerability. Climacteric 2002; 5:60-9 (Pubitemid 34309856)
-
(2002)
Climacteric
, vol.5
, Issue.1
, pp. 60-69
-
-
Baracat, E.C.1
Barbosa, I.C.2
Giordano, M.G.3
Haidar, M.A.4
Marinho, R.M.5
Menegocci, J.C.6
Morais, K.M.7
Tomaz, G.8
Wehba, S.9
-
20
-
-
0037171959
-
Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus
-
DOI 10.1016/S0378-5122(01)00298-5, PII S0378512201002985
-
Mendoza N, Pison JA, Fernandez M, et al. Prospective, randomised study with three HRT regimens in postmenopausal women with an intact uterus. Maturitas 2002;41:289-98 (Pubitemid 34603398)
-
(2002)
Maturitas
, vol.41
, Issue.4
, pp. 289-298
-
-
Mendoza, N.1
Pison, J.A.2
Fernandez, M.3
Sanchez, M.C.4
Malde, J.5
Miranda, J.A.6
-
22
-
-
0037028769
-
Nonspecific medication side effects and the nocebo phenomenon
-
Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecifi c medication side effects and the nocebo phenomenon. JAMA 2002;287: 622-7 (Pubitemid 34252015)
-
(2002)
Journal of the American Medical Association
, vol.287
, Issue.5
, pp. 622-627
-
-
Barsky, A.J.1
Saintfort, R.2
Rogers, M.P.3
Borus, J.F.4
-
23
-
-
31344471005
-
Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects
-
DOI 10.1001/archinte.166.2.155
-
Rief W, Avorn J, Barsky AJ. Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects. Arch Intern Med 2006;166:155-60 (Pubitemid 43144937)
-
(2006)
Archives of Internal Medicine
, vol.166
, Issue.2
, pp. 155-160
-
-
Rief, W.1
Avorn, J.2
Barsky, A.J.3
-
24
-
-
62149130086
-
Gender and the nocebo response following conditioning and expectancy
-
Klosterhalfen S, Kellermann S, Braun S, et al. Gender and the nocebo response following conditioning and expectancy. J Psychosom Res 2009;66:323-8
-
(2009)
J Psychosom Res
, vol.66
, pp. 323-8
-
-
Klosterhalfen, S.1
Kellermann, S.2
Braun, S.3
-
25
-
-
34248580770
-
Prevalence of hot flushes and night sweats around the world: A systematic review
-
DOI 10.1080/13697130601181486, PII 778336742
-
Freeman EW, Sherif K. Prevalence of hot fl ushes and night sweats around the world: A systematic review. Climacteric 2007;10:197-214 (Pubitemid 46752443)
-
(2007)
Climacteric
, vol.10
, Issue.3
, pp. 197-214
-
-
Freeman, E.W.1
Sherif, K.2
-
26
-
-
70350596476
-
Non-hormonal treatment of hot fl ushes in breast cancer survivors: Gabapentin vs. vitamin E
-
Biglia N, Sgandurra P, Peano E, et al. Non-hormonal treatment of hot fl ushes in breast cancer survivors: Gabapentin vs. vitamin E. Climacteric 2009;12:310-18
-
(2009)
Climacteric
, vol.12
, pp. 310-18
-
-
Biglia, N.1
Sgandurra, P.2
Peano, E.3
-
27
-
-
73249150089
-
Safety and effi cacy of black cohosh and red clover for the management of vasomotor symptoms: A randomized controlled trial
-
Geller SE, Shulman LP, van Breemen RB , et al. Safety and effi cacy of black cohosh and red clover for the management of vasomotor symptoms: A randomized controlled trial. Menopause 2009; 16:1156-66
-
(2009)
Menopause
, vol.16
, pp. 1156-66
-
-
Geller, S.E.1
Shulman, L.P.2
Van Breemen, R.B.3
-
28
-
-
77949390613
-
Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: A double-blind, placebo-controlled study
-
Garcia JT, Gonzaga F, Tan D , et al. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: A double-blind, placebo-controlled study. Menopause 2010;17:303-8
-
(2010)
Menopause
, vol.17
, pp. 303-8
-
-
Garcia, J.T.1
Gonzaga, F.2
Tan, D.3
-
29
-
-
0034676813
-
Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial
-
DOI 10.1016/S0140-6736(00)03403-6
-
Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot fl ashes in survivors of breast cancer: A randomised controlled trial. Lancet 2000;356:2059-63 (Pubitemid 32009821)
-
(2000)
Lancet
, vol.356
, Issue.9247
, pp. 2059-2063
-
-
Loprinzi, C.L.1
Kugler, J.W.2
Sloan, J.A.3
Mailliard, J.A.4
LaVasseur, B.I.5
Barton, D.L.6
Novotny, P.J.7
Dakhil, S.R.8
Rodger, K.9
Rummans, T.A.10
Christensen, B.J.11
-
30
-
-
0037087582
-
Phase III evaluation of fluoxetine for treatment of hot flashes
-
DOI 10.1200/JCO.20.6.1578
-
Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fl uoxe tine for treatment of hot fl ashes. J Clin Oncol 2002;20: 1578-83 (Pubitemid 34260538)
-
(2002)
Journal of Clinical Oncology
, vol.20
, Issue.6
, pp. 1578-1583
-
-
Loprinzi, C.L.1
Sloan, J.A.2
Perez, E.A.3
Quella, S.K.4
Stella, P.J.5
Mailliard, J.A.6
Halyard, M.Y.7
Pruthi, S.8
Novotny, P.J.9
Rummans, T.A.10
|